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Dimebon, a compound recently proposed for a treatment of Alzheimer’s 
disorder1,2, was suggested to have memory enhancing properties in pre-
clinical studies3,4. Dimebon increased memory scores3,4,5 and enhanced
neurogenesis5 in rats. 
We aimed to investigate the procognitive effects of dimebon, and to study 
whether repeated or acute intraperitoneal injection of this compound, at 
doses known to increase memory (respectively 0.1 and 0.5 mg/kg), affect 
learning scores in appetitive (Y-Maze) and inhibitory (step-down avoidance) 
tasks in 3-month-old C57BL/6N mice. Additional O-maze, novel cage, open 
field and water consumption tests were carried out to address possible non-
specific effects of dimebon on parameters of drinking, anxiety and 
exploration/locomotion6.
2) Bolus treatment with dimebon at the dose 0.5 mg/kg 
increases the performance in an inhibitory memory task in 
C57BL/6N
1) Subchronic treatment with dimebon accelerates learning
and increases duration of drinking behaviour in an appetitive
memory task in C57BL/6N mice while thirst and behaviours in 
other tests were not affected
• Administration of dimebon via repeated (0.1 mg/kg) and acute (0.5 
mg/kg) i.p. injections respectively increases learning scores in Y-Maze and 
step-down avoidnace tasks in C57BL/6N mice. 
• Acute treatment with dimebon at the dose 0.1 mg/kg did not affect 
learning scores
• No effects of 3-day administration with dimebon were observed on the 
parameters of thirst, anxiety, and exploration/locomotion in 3-month-old
C57BL/6N mice
• Dimebon enhances hippocampus learning in both appetitive and 
inhibitory tasks in C57BL/6N mice
(1) O'Brien JT, Lancet Neurol 2008;7:768–9. 
(2) Doody RS & al., Lancet 2008;372:207–15.
(3) Giorgetti M & al., J Pharmacol Exp Ther 2010;333:748–57.
(4) Schaffhauser H & al., Biochem Pharmacol 2009;78:1035–42.
(5) Pieper AA & al., Cell 2010;142:39–51.
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Figure 1 : Daily administration of dimebon (0.1 mg/kg) decreases latency to reach the 
reward (A), and increases the percentage of correct choices for the arm with the filled
bottle (B) in the Y-Maze in C57BL/6N mice. NaCl: vehicle-treated group, Dim: 
dimebon-treated group.
Figure 2 : Duration of drinking was significantly higher in dimebon-treated group than
in control group (A) while water intake is not affected by repeated (B) or acute (C) 
treatment with dimebon independently of water deprivation. WD: water-deprived, nWD: 
non-water-deprived.
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SDA : 3 mo C57BL/6N mice, Dim 0.1 mg/kg
SDA : 3 mo C57BL/6N mice, Dim 0.5 mg/kg
Figure 3 : C57BL/6N mice acutely treated with dimebon at the dose of 0.5 mg/kg 
showed significantly increased latencies of step down (E), as well as significantly
higher percentage of good learners (F), 24h after training in comparison to the vehicle-
treated group. A lower dose of dimebon (0.1 mg/kg) did not affect the scores of 


































































































































































































































Figure 4 : Mice repeatedly treated with dimebon did not differ from vehicle-treated
animals in the O-maze (A), the novel cage (B), and in the open field (C) tests.
Y-maze apparitus Step-down avoidance
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